Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome

NCT01927861 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Genetic Disorder
Noonan Syndrome

Interventions

DRUG: somatropin

Sponsor

Novo Nordisk A/S